Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study

M. Deraco, C. R. Rossi, E. Pennacchioli, S. Guadagni, D. C. Somers, N. Santoro, F. Raspagliesi, S. Kusamura, M. Vaglini

Research output: Contribution to journalArticlepeer-review

Abstract

Aims and background: The optimal salvage therapy for recurrent ovarian carcinoma has not been clearly established. Response to second-line chemotherapy is low, with a short median survival (8.8-15 months). We investigated the effect of an aggressive approach consisting of surgery followed by intraperitoneal drug delivery and local hyperthermia. Patients and methods: In a phase II clinical study, 27 patients with advanced/recurrent ovarian carcinoma were treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Median patient age was 53 years (range, 30-67) and mean follow-up was 17.4 months (range, 0.3-36.0). Patients had been surgically staged and heavily pretreated with cisplatin-based, taxol-based or taxol/platinum-containing regimens. Nineteen (70%) patients were cytoreduced to minimal residual disease 2/L) + mitomycin C (3.3 mg/m2/L) through a heartlung pump (mean flow of 700 mL/min) for 60 min in the hyperthermic phase (42.5 °C). Results: Two-year overall survival was 55%. Median times to overall progression and local progression were 16 months and 21.8 months, respectively. Variables that affected the overall survival or time to progression were as follows: residual disease (P = 0.00025), patient age (P = 0.04), and lag time between diagnosis and cytoreductive surgery + intraperitoneal hyperthermic perfusion (P = 0.04). Treatment-related morbidity, mortality and acute toxicity (grade II-III) rates were 11%, 4% and 11%, respectively. Eight (89%) of 9 patients had ascites resolution. Conclusion: Our results suggest that cytoreductive surgery + intraperitoneal hyperthermic perfusion is a well-tolerated, feasible and promising alternative in the management of selected patients with recurrent ovarian cancer, but further randomized controlled studies are needed in order to confirm our findings.

Original languageEnglish
Pages (from-to)120-126
Number of pages7
JournalTumori
Volume87
Issue number3
Publication statusPublished - 2001

Keywords

  • Cytoreductive surgery
  • Intraperitoneal hyperthermic perfusion
  • Ovarian cancer
  • Peritoneal carcinomatosis

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study'. Together they form a unique fingerprint.

Cite this